<DOC>
	<DOCNO>NCT00544063</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine , irinotecan , oxaliplatin , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase I trial study side effect best dose capecitabine give together irinotecan oxaliplatin treat patient metastatic cancer .</brief_summary>
	<brief_title>Capecitabine , Irinotecan , Oxaliplatin Treating Patients With Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose dose-limiting toxicity capecitabine . Secondary - Determine recommend phase II dose capecitabine . - Define toxicity profile . - Evaluate potential antitumor activity term objective response , duration response , time disease progression . - Evaluate pharmacokinetic profile capecitabine irinotecan hydrochloride . OUTLINE : This dose-escalation study capecitabine conduct two part . - Part I : Patients receive irinotecan hydrochloride IV 90 minute day 1 oral capecitabine twice daily day 1-7 . Treatment repeat every 2 week 6 month absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos ( 5 dosage ) capecitabine . The maximum tolerated dose ( MTD ) define dose 50 % patient experience toxicity first 2 course therapy . - Part II : Patients receive oxaliplatin IV 2 hour irinotecan hydrochloride IV 90 minute day 1 oral capecitabine day 1-7 . Treatment repeat every 2 week 6 month absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos ( 7 dosage ) capecitabine . The MTD define part I .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically confirm metastatic carcinoma Primary tumor may present No curative therapy available patient achieve response prior standard therapy Nonresectable metastatic disease Measurable , evaluable , nonevaluable disease Exclusion criterion : Symptomatic brain metastasis carcinomatous meningitis PATIENT CHARACTERISTICS : Inclusion criterion : WHO performance status 02 Life expectancy ≥ 12 week ANC ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Bilirubin &lt; 1.25 time upper limit normal ( ULN ) ( 1.5 time ULN due liver metastasis ) Transaminases &lt; 3 time ULN ( 5 time ULN due liver metastasis ) Alkaline phosphatase ≤ 3 time ULN Creatinine ≤ 1.5 time ULN Creatinine clearance &gt; 30 mL/min Not pregnant nursing Fertile patient must use effective contraception Exclusion criterion : Severe concurrent infection major organ failure , include follow : Cardiac disease Diabetic decompensation Clinically active infection Prior severe toxicity fluorouracil Intestinal obstruction subobstruction Malabsorption syndrome Peripheral neuropathy Uncontrolled epilepsy PRIOR CONCURRENT THERAPY : Inclusion criterion : At least 46 week since prior anticancer chemotherapy Exclusions criterion : Prior chemotherapy study drug Prior major intestinal resection Concurrent participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>